Remibrutinib Patent Expiration

Remibrutinib was first introduced by Novartis Pharmaceuticals Corp in its drug Rhapsido on Sep 30, 2025.


Remibrutinib Patents

Given below is the list of patents protecting Remibrutinib, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rhapsido US12419889 Jan 20, 2043 Novartis
Rhapsido US10457647 Nov 13, 2034 Novartis
Rhapsido US9512084 Nov 13, 2034 Novartis



Remibrutinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Remibrutinib Generic API Manufacturers

Given below is the list of companies who have filed for Remibrutinib generic, along with the locations of their manufacturing plants worldwide.